NCT05729932 Cannabis and Opioid Use Disorder
| NCT ID | NCT05729932 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Shanna Babalonis, PhD |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-09-10 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 15 participants in total. It began in 2024-09-10 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.
Eligibility Criteria
Inclusion Criteria: * Current opioid use disorder Exclusion Criteria: * Current medical conditions that require medical management
Contact & Investigator
Shanna Babalonis, PhD
PRINCIPAL INVESTIGATOR
University of Kentucky
Frequently Asked Questions
Who can join the NCT05729932 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05729932 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05729932 currently recruiting?
Yes, NCT05729932 is actively recruiting participants. Contact the research team at pnuzz2@email.uky.edu for enrollment information.
Where is the NCT05729932 trial being conducted?
This trial is being conducted at Lexington, United States.
Who is sponsoring the NCT05729932 clinical trial?
NCT05729932 is sponsored by Shanna Babalonis, PhD. The principal investigator is Shanna Babalonis, PhD at University of Kentucky. The trial plans to enroll 15 participants.